CD437

Min.Order / FOB Price:Get Latest Price

0 Metric Ton	Negotiable

0 Metric Ton

Negotiable

Min.Order :0 Metric Ton
Purity: >98.0%
Payment Terms : T/T

Keywords

AHPN CD437 agonist 2-Naphthalenecarboxylic acid

Quick Details

Appearance:Light yellow to yellow (Solid)
Application:CD437 is a selective Retinoic Acid Receptor γ (RARγ) agonist
PackAge:5mg, 10mg, 25mg, 50mg, 100mg
ProductionCapacity:|Metric Ton|Day
Storage:
Transportation:By Air

Superiority:

Biological Activity:

In Vitro: CD437 is a selective RARγ agonist. Growth inhibition by CD437 in these lung cancer cell lines is apparent after 2 days of treatment with 10 μM CD437. Dose-response experiments demonstrate that CD437 reduces the numbers of H460, SK-MES-1, A549, and H292 cells with 50% inhibitory values of approximately 0.5, 0.4, 3, and 0.85 μM, respectively. Treatment for 72 h with CD437 causes a strong dose-dependent growth inhibition in all melanoma cell lines. At a concentration of 5 μM CD437, only about 5 to 25% of the cells remain viable after 3 d. The concentrations of CD437 required for 50% growth inhibition (IC50) range from 10 μM for MeWo to 0.1 μM for SK-Mel-23 showing the highest sensitivity.

In Vivo: Tumors in CD437-treated mice stop growing, an effect that becomes already statistically significant (P<0.01) at day 13, 3 d after first administration of CD437, and is maintained for more than 3 wk after discontinuation of treatment. Further histologic analysis demonstrates marked c-fos mRNA levels at the tumor-stroma edge in CD437-treated tumors

Details:

CD437 is a synthetic, cell-permeable, retinoid-related molecule that induces tumor growth arrest and apoptosis. The exact molecular basis of the underlying mechanism(s) is not yet well understood, however, studies using ovarian adenocarcinoma cells have shown that CD437/AHPN effectively functions as an ER stress inducer. CD437 is an activator of RAR γ

View All